198 related articles for article (PubMed ID: 8043878)
21. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow.
Welte K; Keever CA; Levick J; Bonilla MA; Merluzzi VJ; Mertelsmann R; Evans R; O'Reilly RJ
Blood; 1987 Nov; 70(5):1595-603. PubMed ID: 3311208
[TBL] [Abstract][Full Text] [Related]
23. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
[TBL] [Abstract][Full Text] [Related]
24. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
Waller EK; Boyer M
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia.
Robinson N; Sanders JE; Benyunes MC; Beach K; Lindgren C; Thompson JA; Appelbaum FR; Fefer A
Blood; 1996 Feb; 87(4):1249-54. PubMed ID: 8608212
[TBL] [Abstract][Full Text] [Related]
26. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
[TBL] [Abstract][Full Text] [Related]
27. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Soiffer RJ; Freedman AS; Neuberg D; Fisher DC; Alyea EP; Gribben J; Schlossman RL; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson KC; Nadler LM; Ritz J
Bone Marrow Transplant; 1998 Jun; 21(12):1177-81. PubMed ID: 9674848
[TBL] [Abstract][Full Text] [Related]
28. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
29. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
Johnson BD; Truitt RL
Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
[TBL] [Abstract][Full Text] [Related]
30. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Barnett L; Heller G
Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
[TBL] [Abstract][Full Text] [Related]
31. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.
Alyea E; Neuberg D; Mauch P; Marcus K; Freedman A; Webb I; Anderson K; Schlossman R; Fisher D; Gribben J; Ritz J; Soiffer R
Biol Blood Marrow Transplant; 2002; 8(3):139-44. PubMed ID: 11939603
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Samuel S; Kapelushnik J; Brautbar C; Or R
Blood; 1996 Mar; 87(6):2195-204. PubMed ID: 8630379
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML.
Kloosterman TC; Martens AC; Osterwalder B; Hagenbeek A
Bone Marrow Transplant; 1994 Dec; 14(6):965-73. PubMed ID: 7711675
[TBL] [Abstract][Full Text] [Related]
34. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Bosserman L; Murray C; Cochran K; Daley J; Ritz J
Blood; 1990 May; 75(10):2076-84. PubMed ID: 1970938
[TBL] [Abstract][Full Text] [Related]
35. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
36. Engraftment following mitoxantrone (Mito) based conditioning for allogeneic bone marrow transplantation (allo-BMT).
Nagler A; Soni S; Samuel S; Or R
Leuk Res; 1998 Mar; 22(3):209-13. PubMed ID: 9619912
[TBL] [Abstract][Full Text] [Related]
37. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
[TBL] [Abstract][Full Text] [Related]
38. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.
Drobyski WR; Ash RC; Casper JT; McAuliffe T; Horowitz MM; Lawton C; Keever C; Baxter-Lowe LA; Camitta B; Garbrecht F
Blood; 1994 Apr; 83(7):1980-7. PubMed ID: 8142664
[TBL] [Abstract][Full Text] [Related]
39. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial.
Nimer SD; Giorgi J; Gajewski JL; Ku N; Schiller GJ; Lee K; Territo M; Ho W; Feig S; Selch M
Transplantation; 1994 Jan; 57(1):82-7. PubMed ID: 8291119
[TBL] [Abstract][Full Text] [Related]
40. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]